Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 8/20 | 0.37 |
| ▸ | METAP1 | P53582 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700073 | 1.00 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL235849 | 0.85 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL2833327 | 0.84 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL13575648 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL17617141 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL2303261 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL17617122 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL30561836 | 0.81 | CA1 (0.42) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL18359202 | 0.81 | CA1 (0.42) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL5079956 | 0.81 | CA1 (0.42) | MGAMGAASIMGAM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030852-B2 | Method for producing fatty alcohol esters of hydroxycarboxylic acids | IOI OLEO GMBH (DE) | 2024-07-09 | — | — | US | disclosed |
| WO-2024137984-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138109-A2 | PHENYL-PYRAZOLE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133200-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130425-A1 | METHODS OF MAKING 2-AMINO-L-(3-HYDROXY-2,6-DIMETHYLPHENYL)-5,6- DIMETHYL-LH-PYRROLO-[2,3-B]PYRIDINE-3-CARBOXAMIDE, A MYTL INHIBITOR | REPARE THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130066-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130064-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130065-A1 | SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129780-A1 | BENZIMIDAZOLE DERIVATIVES AS GPX4 INHIBITORS | SONATA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | disclosed |
| WO-1997036860-A1 | CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036862-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997031891-A1 | PROCESS FOR REGIOSELECTIVE SUBSTITUTION OF TRIFLUOROBENZOATE OR TRIFLUOROBENZONITRILE | MERCK & CO., INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997025992-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0751773-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997018209-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0751773-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |
| EP-0304155-A2 | Cephalosporin compounds, process for their preparation and their pharmaceutical compositions | ZENECA Pharma S.A. (FR) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030852-B2 | Method for producing fatty alcohol esters of hydroxycarboxylic acids | FASN, HSD17B12, SCD | ALDH1A1 144/4885LMNA 2304/4885HSD17B10 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.